Viral Hepatitis

You have full text access to this OnlineOpen article

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy†‡§

  1. Donald M. Jensen1,¶,*,
  2. Timothy R. Morgan2,
  3. Patrick Marcellin3,
  4. Paul J. Pockros4,
  5. K. Rajender Reddy5,
  6. Stephanos J. Hadziyannis6,
  7. Peter Ferenci7,
  8. Andrew M. Ackrill8,
  9. Bernard Willems9

Article first published online: 20 APR 2006

DOI: 10.1002/hep.21159

Issue

Hepatology

Hepatology

Volume 43, Issue 5, pages 954–960, May 2006

Additional Information

How to Cite

Jensen, D. M., Morgan, T. R., Marcellin, P., Pockros, P. J., Reddy, K. R., Hadziyannis, S. J., Ferenci, P., Ackrill, A. M. and Willems, B. (2006), Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy. Hepatology, 43: 954–960. doi: 10.1002/hep.21159

Author Information

  1. 1

    Center for Liver Diseases, University of Chicago, Chicago, IL

  2. 2

    VA Medical Center, Long Beach, CA

  3. 3

    Hôpital Beaujon, Clichy, France

  4. 4

    The Scripps Clinic, La Jolla, CA

  5. 5

    University of Pennsylvania, Philadelphia, PA

  6. 6

    Henry Dunant Hospital, Athens, Greece

  7. 7

    Department of Internal Medicine IV, Medical University of Vienna, Vienna, Austria

  8. 8

    Roche, Welwyn, UK

  9. 9

    Centre Hospitalier de l'Université de Montréal, Montréal QC, Canada

  1. fax: 773-834-1288.

*Director, Center for Liver Diseases, University of Chicago Hospitals, 5841 S. Maryland, MC 7120, Chicago, IL 60637

  1. †

    Potential conflict of interest: Dr. Willems advises and received grants from Roche. Dr. Jensen is a consultant for and received grants from Roche. Dr. Reddy advises and is on the speakers' bureau for Roche. He also advises for Schering-Plough. Dr. Ferenci consults for, advises, is on the speakers' bureau for, and received grants from Roche. Dr. Morgan is on the speakers' bureau for and received grants from Roche and Schering-Plough. Prof. Hadziyannis consults for, advises, is on the speakers' bureau for, and received grants from Roche. He also received grants from Schering-Plough. Dr. Pockros is a consultant for Roche, and is on the speakers' bureau for and received grants from Roche and Schering-Plough. Dr. Marcellin advises, is on the speakers' bureau for, and received grants from Roche.

  2. ‡

    This article has been corrected since its original publication. Please see Hepatology 2006;43:1410 for further details.

  3. §

    See Editorial on Page 909

Publication History

  1. Issue published online: 20 APR 2006
  2. Article first published online: 20 APR 2006
  3. Manuscript Accepted: 10 FEB 2006
  4. Manuscript Received: 7 NOV 2005

Funded by

  • Roche (Basel, Switzerland)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (416K)

References

  • 1
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–982.
  • 2
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–355.
  • 3
    Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. HEPATOLOGY 2004; 39: 1147–1171.
    Direct Link:
  • 4
    Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 2004; 189: 964–970.
  • 5
    Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Gonçales FLJ, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon α-2a (40KD)/ribavirin. J Hepatol 2005; 43: 425–433.
  • 6
    Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon α-2b plus ribavirin in patients with hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97–103.
  • 7
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965.
  • 8
    Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, Moreno R, Romero-Gomez M, et al. Longer treatment duration with peginterferon α-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) in naive patients with chronic hepatitis C and detectable HCV RNA by week 4 of therapy: final results of the randomized, multicenter TERAVIC-4 study [Abstract no. 126]. HEPATOLOGY 2004; 40( Suppl 1): 218A.
View Full Article (HTML) Get PDF (416K)